Sickle cell anemia
Sickle cell anemia is one of the most dangerous and rare genetic diseases found in some people. The people suffering from this lethal disease can go through extreme conditions and require a periodic blood transfusion. In this condition, the RBCs of a person are unable to break down the oxygen that is required for the body and that can cause a serious condition for the very working structure of the body. There have been many drugs developed for the disease but only some of them are capable of sustaining the life of the patient.
A new drug developed by Imara
The biotech company Imara has developed a new drug for sickle cell disease and is looking forward to the commercial launch of the same in the market shortly. The news has caused a tremendous rise in the stock prices of the company and is looking at a profitable quarter of the year excluding the coronavirus pandemic. The sickle cell disease is characterized by the total absence or lack of hemoglobin in the RBCs of the person. The new drug is aimed at exponentially increasing the number of RBCs in the person’s blood and also increase the presence of hemoglobin in them.
The company has moved onto phase 2 of clinical trials and is testing the new drugs on the people suffering from sickle cell disease. The company has been receiving positive reviews from the test subjects and they are looking forward to expanding their tests and have set a predictive date of the middle of 2020 to enter the next phase of clinical trials. The developed drug will not only be limited to the treatment of the sickle cell disease but also be useful for the beta-thalassemia.
The company is expected to witness a growth in its stock prices due to the impending market launch of the drug and despite getting competition from major players, the company is expecting to see profits in the last quarter of this year. As per the market study on sickle cell anemia market by Value Market Research, there are other companies also involved in the development of various genetic editing treatments for curing sickle cell anemia and beta-thalassemia but they are not expected to make an entry in the market by this year.
The drug developed by Imara is at an advantage over the advanced techniques offered by some companies and that is because this drug needs to be taken orally instead of the complex procedures that the other treatments require. So this new drug is more preferable for patients with mild genetic conditions and easy to implement.
Nishtha Sarabhai after working for three years in a Bank switched to writing to balance her work and home. She is a mother of two beautiful kids. She enjoys writing on Aerospace, Science and new invcentions. She has been with VMR news since its inception.